JPS5984883A - ピリダジノン誘導体又はその塩類 - Google Patents
ピリダジノン誘導体又はその塩類Info
- Publication number
- JPS5984883A JPS5984883A JP19413782A JP19413782A JPS5984883A JP S5984883 A JPS5984883 A JP S5984883A JP 19413782 A JP19413782 A JP 19413782A JP 19413782 A JP19413782 A JP 19413782A JP S5984883 A JPS5984883 A JP S5984883A
- Authority
- JP
- Japan
- Prior art keywords
- salts
- pyridazinone derivatives
- present
- rate
- pyridazinone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- AAILEWXSEQLMNI-UHFFFAOYSA-N 1h-pyridazin-6-one Chemical class OC1=CC=CN=N1 AAILEWXSEQLMNI-UHFFFAOYSA-N 0.000 title claims description 6
- 150000003839 salts Chemical class 0.000 title claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 10
- 241000282472 Canis lupus familiaris Species 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- 239000000496 cardiotonic agent Substances 0.000 description 6
- 210000003540 papillary muscle Anatomy 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 230000002861 ventricular Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 4
- 241000700198 Cavia Species 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- -1 N-/'tilpyrrolidone Chemical compound 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000001746 atrial effect Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 241000700199 Cavia porcellus Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- ATHHXGZTWNVVOU-UHFFFAOYSA-N N-methylformamide Chemical compound CNC=O ATHHXGZTWNVVOU-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 210000005246 left atrium Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 241000282465 Canis Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 238000007239 Wittig reaction Methods 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 210000001008 atrial appendage Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000000297 inotrophic effect Effects 0.000 description 1
- 239000004041 inotropic agent Substances 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- JABYJIQOLGWMQW-UHFFFAOYSA-N undec-4-ene Chemical compound CCCCCCC=CCCC JABYJIQOLGWMQW-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP19413782A JPS5984883A (ja) | 1982-11-05 | 1982-11-05 | ピリダジノン誘導体又はその塩類 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP19413782A JPS5984883A (ja) | 1982-11-05 | 1982-11-05 | ピリダジノン誘導体又はその塩類 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5984883A true JPS5984883A (ja) | 1984-05-16 |
| JPH0348190B2 JPH0348190B2 (enrdf_load_stackoverflow) | 1991-07-23 |
Family
ID=16319519
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP19413782A Granted JPS5984883A (ja) | 1982-11-05 | 1982-11-05 | ピリダジノン誘導体又はその塩類 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5984883A (enrdf_load_stackoverflow) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013207229A (ja) * | 2012-03-29 | 2013-10-07 | Fujitsu Ltd | 電子システム及び電子装置 |
-
1982
- 1982-11-05 JP JP19413782A patent/JPS5984883A/ja active Granted
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013207229A (ja) * | 2012-03-29 | 2013-10-07 | Fujitsu Ltd | 電子システム及び電子装置 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0348190B2 (enrdf_load_stackoverflow) | 1991-07-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4404203A (en) | Substituted 6-phenyl-3(2H)-pyridazinones useful as cardiotonic agents | |
| US4397854A (en) | Substituted 6-phenyl-3(2H)-pyridazinones useful as cardiotonic agents | |
| JP3119738B2 (ja) | Ｎ−フェニル−２−シアノ−３−ヒドロキシクロトンアミド誘導体および免疫調整性を有する医薬品としてのその使用 | |
| JPS60197672A (ja) | ビリダジノン誘導体またはその塩類 | |
| JPS5984883A (ja) | ピリダジノン誘導体又はその塩類 | |
| JPS60174781A (ja) | 強心および抗高血圧オキサジアジノン化合物 | |
| JPH0545585B2 (enrdf_load_stackoverflow) | ||
| JPS61183222A (ja) | ピロール‐３‐カルボキシレート強心剤 | |
| US3137621A (en) | Method of treating colic with trihydroxyacetophenones | |
| JPS6314774A (ja) | ピリダジノン誘導体又はその塩類 | |
| JPS644517B2 (enrdf_load_stackoverflow) | ||
| EP0085985A1 (en) | Pyridazinone derivatives, pharmaceutically acceptable salts thereof and pharmaceutical compositions comprising said compounds | |
| JPS5815913A (ja) | 強心剤 | |
| JPS60197681A (ja) | ピリジン誘導体またはその塩類 | |
| JPH0134969B2 (enrdf_load_stackoverflow) | ||
| US3629443A (en) | Therapeutic composition containing a mandelamidine derivative | |
| JPS6078982A (ja) | ナフタレニルイミダゾピリジンおよびその誘導体ならびにその製造法 | |
| JPH0259574A (ja) | ピラジノン誘導体又はその塩類 | |
| US5280043A (en) | Sulphonamido containing phenylalkanoic acids as thromboxane A2 antagonists | |
| JPH024577B2 (enrdf_load_stackoverflow) | ||
| JPS649290B2 (enrdf_load_stackoverflow) | ||
| EP0251126B1 (en) | 1,7-substituted heptyne-2-ones | |
| JPS5815914A (ja) | 強心剤 | |
| JPS63218666A (ja) | ピリダジノン誘導体またはその塩類 | |
| WO1994009784A1 (en) | Platelet aggregation inhibitor |